MIRA INFORM REPORT

 

 

Report Date :

06.07.2013

 

IDENTIFICATION DETAILS

 

Name :

MAPLE PHARMACEUTICALS (PRIVATE) LIMITED

 

 

Registered Office :

Plot # 147, Sector 23, Korangi Industrial Area, Karachi,

 

 

Country :

Pakistan

 

 

Year of Incorporation :

2003

 

 

Com. Reg. No.:

0058884

 

 

Legal Form :

Private Limited Company

 

 

Line of Business :

Manufacture & Marketing of Pharmaceutical Products

 

 

No. of Employees :

224

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

Pakistan

B2

B2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

PAKISTAN - ECONOMIC OVERVIEW

 

Decades of internal political disputes and low levels of foreign investment have led to slow growth and underdevelopment in Pakistan. Agriculture accounts for more than one-fifth of output and two-fifths of employment. Textiles account for most of Pakistan's export earnings, and Pakistan's failure to expand a viable export base for other manufactures has left the country vulnerable to shifts in world demand. Official unemployment is under 6%, but this fails to capture the true picture, because much of the economy is informal and underemployment remains high. Over the past few years, low growth and high inflation, led by a spurt in food prices, have increased the amount of poverty - the UN Human Development Report estimated poverty in 2011 at almost 50% of the population. Inflation has worsened the situation, climbing from 7.7% in 2007 to almost 12% for 2011, before declining to 10% in 2012. As a result of political and economic instability, the Pakistani rupee has depreciated more than 40% since 2007. The government agreed to an International Monetary Fund Standby Arrangement in November 2008 in response to a balance of payments crisis. Although the economy has stabilized since the crisis, it has failed to recover. Foreign investment has not returned, due to investor concerns related to governance, energy, security, and a slow-down in the global economy. Remittances from overseas workers, averaging about $1 billion a month since March 2011, remain a bright spot for Pakistan. However, after a small current account surplus in fiscal year 2011 (July 2010/June 2011), Pakistan's current account turned to deficit in fiscal year 2012, spurred by higher prices for imported oil and lower prices for exported cotton. Pakistan remains stuck in a low-income, low-growth trap, with growth averaging about 3% per year from 2008 to 2012. Pakistan must address long standing issues related to government revenues and energy production in order to spur the amount of economic growth that will be necessary to employ its growing and rapidly urbanizing population, more than half of which is under 22. Other long term challenges include expanding investment in education and healthcare, adapting to the effects of climate change and natural disasters, and reducing dependence on foreign donors.

Source : CIA

Business Name

 

MAPLE PHARMACEUTICALS (PRIVATE) LIMITED

 

 

Full Address       

 

Registered Address & Factory

Plot # 147, Sector 23, Korangi Industrial Area, Karachi, Pakistan

                       

Tel #

92 (21) 35113933, 35113936

Fax #

92 (21) 35056670, 35056676

 

 

Short Description Of Business

 

a.

Nature of Business       

Manufacture & Marketing of Pharmaceutical Products

b.

Year Established

2003

c.

Registration #

0058884

 

 

Branches

           

In Lahore & Islamabad

 

           

Auditors

 

M/s Muhammad Farooq & Co.

(Chartered Accountants)

208-209, 2nd Floor, Dada Chambers, M.A. Jinnah Road, Karachi, Pakistan

 

 

Legal Status

 

Subject Company was established as a Partnership business in 2003 then afterwards its legal status was converted to Private Limited Company in 2006

 

6.

Authorized Capital           

Rs. 200,000,000/- divided into 2,000,000 shares of Rs. 100/- each

 

Issued & Paid up Capital

Rs. 175,400,000/- divided into 1,754,000 shares of Rs. 100/- each

 

 

Details of Chief Executive / Directors

 

Names

Designation

Mr. Shafiuddin Feroze

 

Mr. Mehtabuddin Feroze

 

Mr. Taufiq Feroze

 

Mr. Sohail Feroz

 

Mr. Mohsin Shafi Feroze

 

Mr. Tehseen Feroze

 

Mr. Ahsan Feroz

 

Mr. Raheel Shafi

Chief Executive

 

Director

 

Director

 

Director

 

Director

 

Director

 

Director

 

Director

 

Shareholders                

 

Names

No. of Shares

Mr. Mehtabuddin Feroze

 

Mr. Shafiuddin Feroze

 

Mr. Sohail Feroze

 

Mr. Taufiq Feroze

 

Mr. Sultan Feroze

 

Mr. Mohsin Shafi Feroze

 

Mr. Tehseen Feroze

 

Mr. Ahsan Feroz

 

Mr. Raheel Shafi

 

Mr. Munir Mehtab Feroze

 

Mr. Sadiq Mehtab Feroze

 

Mr. Tariq Mehtab Feroze

210,480

 

595,480

 

175,400

 

175,400

 

210,480

 

87,920

 

220

 

87,920

 

220

 

70,160

 

70,160

 

70,160

 

 

Associates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

 

A.         Subsidiary

 

                        None                                             

           

B.         Associated Companies

 

(1)   Efroze Chemical Industries (Pvt) Limited, Pakistan.

(2)   S. Ejazuddin & Co., Pakistan.

(3)   Otsuka Pakistan Limited, Pakistan.

(4)   Health Care Products, Pakistan.

(5)   Multi-Tech Marketing Services, Pakistan.

(6)   Uniferoz, Pakistan.

(7)   Efrotech, Pakistan.

(8)   Hospital Supply Corporation, Pakistan.

 

 

Products / Services

 

Manufacture & marketing of Pharmaceutical Products.

 

 

Number of Employees

           

224

 

 

Affiliation with

 

(1) MAPLE PHARMACEUTICALS INC. TORONTO, CANADA.

 

 

Annual Production Volume

 

The capacity and production of the company’s plant is indeterminable as it involves varying processes of manufacture.

 

 

Annual Sales Volume

 

Year

In Pak Rupees

2012

351,493,369/-

 

Distributors Network

 

Mainly exist at major cities of Pakistan

 

Bankers

 

(1) KASB Bank Limited, Pakistan.

(2) Habib Bank Limited, Pakistan.

(3) Allied Bank Limited, Pakistan.

(4) MCB Bank Limited, Pakistan.

(5) Bank Al-falah Limited, Pakistan.

 

 

Memberships

 

·         Pakistan Pharmaceutical Manufacturers Association.(PPMA)

·         Karachi Chamber of Commerce & Industry.(KCCI)

 

 

Foreign Exchange Rates

 

Currency

 

Unit

Pakistani Rupee

US Dollar

1

           Rs. 100.30

UK Pound

1

           Rs. 153.50

Euro

1

           Rs. 130.50

 

Comments

 

Efroze Group enjoys good reputation in Pakistan as well as in abroad. All the directors of the Company are reported as qualified, experienced and resourceful businessmen. Payments are usually correct and as per commitments. The Company can be considered for normal business dealings at usual trade terms and conditions.

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.60.34

UK Pound

1

Rs.90.78

Euro

1

Rs.77.81

 

 

INFORMATION DETAILS

 

Report Prepared by :

PRL

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.